Departments of Radiology and Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Alzheimers Dement. 2013 Jul;9(4):e106-9. doi: 10.1016/j.jalz.2013.06.001.
Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging previously published appropriate use criteria for amyloid PET as an important tool for increasing the certainty of a diagnosis of Alzheimer disease in specific patient populations. Here, the task force further clarifies and expands 3 topics discussed in the original paper: first, defining dementia experts and their use of proper documentation to demonstrate the medical necessity of an amyloid PET scan; second, identifying a specific subset of individuals with mild cognitive impairment for whom an amyloid PET scan is appropriate; and finally, developing educational programs to increase awareness of the amyloid PET appropriate use criteria and providing instructions on how this test should be used in the clinical decision-making process.
淀粉样蛋白 PET 成像（Amyloid PET imaging）是一种新型诊断测试，可在活体人类中检测阿尔茨海默病的两种明确病理病变之一，即大脑中的淀粉样蛋白-β沉积。阿尔茨海默病协会（Alzheimer's Association）和核医学与分子成像学会（Society for Nuclear Medicine and Molecular Imaging）的淀粉样蛋白成像工作组之前发布了淀粉样蛋白 PET 的适当使用标准，将其作为在特定患者群体中增加阿尔茨海默病诊断确定性的重要工具。在这里，工作组进一步澄清和扩展了原始论文中讨论的 3 个主题：首先，定义痴呆症专家及其使用适当的文件来证明淀粉样蛋白 PET 扫描的医学必要性；其次，确定轻度认知障碍的特定亚组人群，他们适合进行淀粉样蛋白 PET 扫描；最后，制定教育计划，提高对淀粉样蛋白 PET 适当使用标准的认识，并就如何在临床决策过程中使用该测试提供说明。
